)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Pharma Mar
Pharma Mar (PHM) investor relations material
Pharma Mar Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary1 Aug, 2026
Strategic vision and leadership
Focused on marine-derived oncology drugs, aiming to remain a global leader in marine medicinal innovation.
Fully integrated commercial-stage biotech with a diversified pipeline and three approved oncology products.
Strong European sales force and established commercial presence.
Product portfolio and pipeline
Three approved oncology products: Yondelis (trabectedin), Aplidin (plitidepsin), and Zepzelca (lurbinectedin).
Expanding pipeline includes late and early-stage assets, with ongoing trials in solid tumors and sarcomas.
Lurbinectedin approved for first-line maintenance in SCLC in both US and EU, with further potential indications under study.
Clinical trial highlights
IMforte Phase 3 trial showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) for lurbinectedin plus atezolizumab in SCLC.
Safety profile manageable, with most adverse events not leading to discontinuation; practice-changing results noted by key opinion leaders.
SaLuDo trial in leiomyosarcoma completed recruitment, with regulatory submissions and data readouts expected in 2026-2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pharma Mar
- Recurring revenue up 18% to €85.1M, net profit at €0.6M, ZepzelcaⓇ drives growth.PHM
Q2 2026 - Revenue up 10%, EBITDA and net income positive, Zepzelca® gains EMA support.PHMQ1 2026
- Positive Phase 3 results and strong revenues drive expansion in marine-derived oncology.PHMCorporate presentation
- Lurbinectedin's Phase 3 success in SCLC and strong financials drive global oncology growth.PHMCorporate presentation
- Revenue up 27%, EBITDA up fivefold, and net profit up 187% on Zepzelca milestones.PHMQ4 2025
- Revenue up 8% and EBITDA up 14%, with strong R&D and positive trial results.PHMQ3 2024
- Revenue up 1% to €80.8M, net profit €3.5M, royalties up 16%, and R&D spend increased.PHMQ2 2024
- Recurring revenue up 19%, EBITDA up 60%, and strong cash position at €142.2M.PHMQ1 2025
- Net profit rose to €26.2M as revenue, royalties, and licensing income hit record highs.PHMQ4 2024
Next Pharma Mar earnings date
Q3 202629 Oct, 2026
Pharma Mar
Next Pharma Mar earnings date
Q3 202629 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage